Compare The Coca-Cola Co K (KO) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Spyre Therapeutics Inc. Common Stock — how do they compare? The Coca-Cola Co K trades at $93.26 (market cap $394.89B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: The Coca-Cola Co K is far larger — about 53.7× Spyre Therapeutics Inc. Common Stock's market cap, and The Coca-Cola Co K pays a 2.31% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KO | SYRE | |
|---|---|---|
Market Cap | $394.89B | $7.35B |
Volume | 14,523,087 | 1,624,631 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $108.92 |
52-Week Low | $67.08 | $22.18 |
Typical Hold Time | 154 Days | 0 Days |
Enterprise Value | $422.06B | $6.35B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $90.11, up 0.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $0.97, beating estimates, and maintains robust profitability with a 28.56% net income margin. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook is positive, supported by consistent earnings beats, a high analyst buy rating (60.42%), and a $95.75 consensus price target. Risks include elevated valuation multiples and regional demand variability. The stock offers a reliable dividend, with a payout increase for 64 consecutive years.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
